ES2160602T3 - Derivados de quinolona y acridinona para el tratamiento de la incontinencia urinaria. - Google Patents

Derivados de quinolona y acridinona para el tratamiento de la incontinencia urinaria.

Info

Publication number
ES2160602T3
ES2160602T3 ES93922605T ES93922605T ES2160602T3 ES 2160602 T3 ES2160602 T3 ES 2160602T3 ES 93922605 T ES93922605 T ES 93922605T ES 93922605 T ES93922605 T ES 93922605T ES 2160602 T3 ES2160602 T3 ES 2160602T3
Authority
ES
Spain
Prior art keywords
treatment
urinary incontinence
quinolona
acridinone
derivatives
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES93922605T
Other languages
English (en)
Inventor
Cyrus John Ohnmacht
Diane Amy Trainor
Janet Marie Forst
Mark Morris Stein
Robert Joseph Harris
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB9221989A external-priority patent/GB9221989D0/en
Priority claimed from GB939308065A external-priority patent/GB9308065D0/en
Application filed by AstraZeneca AB filed Critical AstraZeneca AB
Application granted granted Critical
Publication of ES2160602T3 publication Critical patent/ES2160602T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D219/00—Heterocyclic compounds containing acridine or hydrogenated acridine ring systems
    • C07D219/04—Heterocyclic compounds containing acridine or hydrogenated acridine ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the ring system
    • C07D219/06—Oxygen atoms
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02E—REDUCTION OF GREENHOUSE GAS [GHG] EMISSIONS, RELATED TO ENERGY GENERATION, TRANSMISSION OR DISTRIBUTION
    • Y02E60/00—Enabling technologies; Technologies with a potential or indirect contribution to GHG emissions mitigation
    • Y02E60/30—Hydrogen technology
    • Y02E60/36—Hydrogen production from non-carbon containing sources, e.g. by water electrolysis

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

SE PRESENTAN COMPUESTOS DE LA FORMULA (I) EN LA QUE R2, R3, R4, R10 Y R11 TIENEN CUALQUIERA DE LOS SIGNIFICADOS DADOS EN LAS ESPECIFICACIONES, ASI COMO SUS SALES FARMACOLOGICAMENTE ACEPTABLES, QUE SON UTILES PARA EL TRATAMIENTO DE LA INCONTINENCIA URINARIA. TAMBIEN SE PRESENTAN COMPOSICIONES FARMACEUTICAS, PROCESOS PARA PREPARAR LOS COMPUESTOS DE LA FORMULA (I) E INTERMEDIARIOS.
ES93922605T 1992-10-20 1993-10-14 Derivados de quinolona y acridinona para el tratamiento de la incontinencia urinaria. Expired - Lifetime ES2160602T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9221989A GB9221989D0 (en) 1992-10-20 1992-10-20 Heterocyclic derivatives
GB939308065A GB9308065D0 (en) 1993-04-20 1993-04-20 Heterocyclic derivatives

Publications (1)

Publication Number Publication Date
ES2160602T3 true ES2160602T3 (es) 2001-11-16

Family

ID=26301823

Family Applications (1)

Application Number Title Priority Date Filing Date
ES93922605T Expired - Lifetime ES2160602T3 (es) 1992-10-20 1993-10-14 Derivados de quinolona y acridinona para el tratamiento de la incontinencia urinaria.

Country Status (21)

Country Link
EP (1) EP0665834B1 (es)
JP (1) JP3315699B2 (es)
KR (1) KR100296657B1 (es)
AT (1) ATE201671T1 (es)
AU (1) AU673696B2 (es)
CA (1) CA2146763C (es)
DE (1) DE69330282T2 (es)
DK (1) DK0665834T3 (es)
ES (1) ES2160602T3 (es)
FI (1) FI110940B (es)
GB (2) GB9318935D0 (es)
GR (1) GR3036442T3 (es)
HK (1) HK1013996A1 (es)
HU (2) HU215386B (es)
IL (1) IL107287A (es)
NO (1) NO303222B1 (es)
NZ (1) NZ256719A (es)
PT (1) PT665834E (es)
RU (1) RU2124006C1 (es)
TW (1) TW261616B (es)
WO (1) WO1994008966A1 (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9407432D0 (en) * 1994-04-14 1994-06-08 Zeneca Ltd Heterocyclic derivative
GB9707695D0 (en) * 1996-08-07 1997-06-04 Hoffmann La Roche Tricyclic dione derivatives
US6265417B1 (en) 1997-12-18 2001-07-24 Abbott Laboratories Potassium channel openers
IL135985A0 (en) * 1997-12-18 2001-05-20 Abbott Lab Potassium channel openers
US6593335B1 (en) 1997-12-18 2003-07-15 Abbott Laboratories Potassium channel openers
CA2348165A1 (en) * 1998-10-28 2000-05-04 Abbott Laboratories Dihydropyridine compounds and methods of use
US6642222B2 (en) 1998-10-28 2003-11-04 Abbott Laboratories Pyrano, piperidino, and thiopyrano compounds and methods of use
US6191140B1 (en) 1998-10-28 2001-02-20 Abbott Laboratories Pyrano, piperidino, and thiopyrano compounds and methods of use
US6518279B2 (en) 1999-03-04 2003-02-11 Abbott Laboratories Cyclopentanone dihydropyridine compounds useful as potassium channel openers
US7074931B2 (en) 2000-08-02 2006-07-11 Astrazeneca Ab Process for asymmetric synthesis of substituted 1,4 -dihydropyridines
JP2004505100A (ja) 2000-08-02 2004-02-19 アストラゼネカ・アクチエボラーグ アルファ，ベータ−不飽和ケトンの合成法
FR2856687B1 (fr) * 2003-06-25 2005-09-16 Servier Lab Nouveaux derives de benzo[a]pyrano[3,2-h]acridin-7-one, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
WO2006117023A1 (en) 2005-05-04 2006-11-09 N.V. Organon Dihydropyridine derivatives
UA92008C2 (en) * 2005-05-04 2010-09-27 Н.В. Органон 4-PHENYL-5-OXO-l,4,5,6,7,8-HEXAHYDROQUINOLINE DERIVATIVES AS MEDICAMENTS FOR THE TREATMENT OF INFERTILITY
UA92009C2 (ru) * 2005-05-04 2010-09-27 Н.В. Органон Производные 4-фенил-5-оксо-1,4,5,6,7,8-гексагидрохинолина для лечения бесплодия
UA92007C2 (ru) * 2005-05-04 2010-09-27 Н.В. Органон Производные 4-фенил-5-оксо-1,4,5,6,7,8-гексагидрохинолина для лечения бесплодности
US8916550B2 (en) 2005-05-09 2014-12-23 Hydra Biosciences, Inc. Compounds for modulating TRPV3 function
EP1888575A2 (en) * 2005-05-09 2008-02-20 Hydra Biosciences, Inc. Compounds for modulating trpv3 function
US11976041B1 (en) 2023-10-23 2024-05-07 King Faisal University 9-(5-bromo-2-hydroxyphenyl)-10-[3-(dimethylamino)propyl]-3,4,6,7,9,10-hexahydroacridine-1,8(2H,5H)-dione as an antimicrobial compound

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2003148A1 (de) * 1970-01-24 1971-07-29 Bayer Ag Neue 1,4-Dihydropyridinderivate
DE2018738A1 (en) * 1970-04-18 1971-10-28 Farbenfabriken Bayer Ag, 5090 Leverkusen Hydrogenated pyridines, quinolines andacridi
GB9220570D0 (en) * 1991-10-21 1992-11-11 Ici Plc Therapeutic agent
EP0539154B1 (en) * 1991-10-21 1997-12-29 Zeneca Limited Acridine-1,8-dione-derivatives as therapeutic agents

Also Published As

Publication number Publication date
AU5154593A (en) 1994-05-09
IL107287A0 (en) 1994-01-25
FI110940B (fi) 2003-04-30
CA2146763A1 (en) 1994-04-28
EP0665834B1 (en) 2001-05-30
EP0665834A1 (en) 1995-08-09
PT665834E (pt) 2001-11-30
DE69330282T2 (de) 2002-01-10
RU2124006C1 (ru) 1998-12-27
RU95110937A (ru) 1997-03-10
HU211741A9 (en) 1995-12-28
DK0665834T3 (da) 2001-09-10
HU9302933D0 (en) 1993-12-28
CA2146763C (en) 2005-10-04
GB9319938D0 (en) 1993-11-17
FI951858A (fi) 1995-04-19
NO951484D0 (no) 1995-04-19
HUT70026A (en) 1995-09-28
KR100296657B1 (ko) 2001-10-24
HK1013996A1 (en) 1999-09-17
NZ256719A (en) 1996-11-26
JPH08502282A (ja) 1996-03-12
HU215386B (hu) 1998-12-28
IL107287A (en) 2000-09-28
DE69330282D1 (de) 2001-07-05
TW261616B (es) 1995-11-01
ATE201671T1 (de) 2001-06-15
NO951484L (no) 1995-06-19
JP3315699B2 (ja) 2002-08-19
FI951858A0 (fi) 1995-04-19
NO303222B1 (no) 1998-06-15
WO1994008966A1 (en) 1994-04-28
AU673696B2 (en) 1996-11-21
GB9318935D0 (en) 1993-10-27
GR3036442T3 (en) 2001-11-30

Similar Documents

Publication Publication Date Title
ES2160602T3 (es) Derivados de quinolona y acridinona para el tratamiento de la incontinencia urinaria.
ATE248837T1 (de) Chinuclidin-acrylamide
DK0524781T3 (da) Terapeutiske amider
GB9305295D0 (en) Therapeutic compounds
ATE170852T1 (de) Benzolsulfonamid-derivate zur behandlung der blaseninstabilität
ATE161531T1 (de) Acridine-1,8-dionderivate als therapeutisches mittel
DE69330601D1 (de) Serotoninergische ergolin derivate
GB9310069D0 (en) Heterocyclic compounds
CA2120229A1 (fr) Derives de methylpiperazinoazepine, leur preparation et leur utilisation
FI952856A0 (fi) Uudet triatsolopyrimidonit, niiden valmistus ja käyttö

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 665834

Country of ref document: ES